Literature DB >> 25493232

Chemotherapy advances in locally advanced head and neck cancer.

Peter Georges1, Kumar Rajagopalan1, Chady Leon1, Priya Singh1, Nadir Ahmad1, Kamyar Nader1, Gregory J Kubicek1.   

Abstract

The management of locally advanced unresectable head and neck squamous cell cancer (HNSCC) continues to improve. One of the major advances in the treatment of HNSCC was the addition of chemotherapy to radiation in the treatment of non-surgical patients. The majority of the data regarding chemotherapy in HNSCC involve cisplatin chemotherapy with concurrent radiation. However, several new approaches have included targeted therapy against epidermal growth factor receptor and several recent studies have explored the role of induction chemotherapy in the treatment of HNSCC. The purpose of this article is to provide an overview of the role of chemotherapy in the treatment of locally advanced HNSCC.

Entities:  

Keywords:  Chemotherapy; Head and neck cancer; Induction

Year:  2014        PMID： 25493232      PMCID： PMC4259956          DOI： 10.5306/wjco.v5.i5.966

Source DB:  PubMed          Journal:  World J Clin Oncol        ISSN： 2218-4333


  23 in total

1.  RTOG 0522: a randomized phase III trial of concurrent accelerated radiation and cisplatin versus concurrent accelerated radiation, cisplatin, and cetuximab [followed by surgery for selected patients] for Stage III and IV head and neck carcinomas.

Authors: 
Journal:  Clin Adv Hematol Oncol       Date:  2007-02

2.  Recent advances in head and neck cancer.

Authors:  Robert I Haddad; Dong M Shin
Journal:  N Engl J Med       Date:  2008-09-11       Impact factor: 91.245

3.  Induction chemotherapy in head and neck cancer.

Authors:  Robert I Haddad; Marshall R Posner
Journal:  J Clin Oncol       Date:  2009-07-13       Impact factor: 44.544

Review 4.  Induction chemotherapy in locally advanced squamous cell cancer of the head and neck: evolution of the sequential treatment approach.

Authors:  Marshall R Posner; Robert I Haddad; Lori Wirth; Charles M Norris; Laura A Goguen; Anand Mahadevan; Christopher Sullivan; Roy B Tishler
Journal:  Semin Oncol       Date:  2004-12       Impact factor: 4.929

5.  Induction chemotherapy followed by concurrent chemoradiotherapy (sequential chemoradiotherapy) versus concurrent chemoradiotherapy alone in locally advanced head and neck cancer (PARADIGM): a randomised phase 3 trial.

Authors:  Robert Haddad; Anne O'Neill; Guilherme Rabinowits; Roy Tishler; Fadlo Khuri; Douglas Adkins; Joseph Clark; Nicholas Sarlis; Jochen Lorch; Jonathan J Beitler; Sewanti Limaye; Sarah Riley; Marshall Posner
Journal:  Lancet Oncol       Date:  2013-02-13       Impact factor: 41.316

Review 6.  The role of cetuximab in the treatment of squamous cell cancer of the head and neck.

Authors:  Barbara Burtness
Journal:  Expert Opin Biol Ther       Date:  2005-08       Impact factor: 4.388

7.  A Radiation Therapy Oncology Group (RTOG) phase III randomized study to compare hyperfractionation and two variants of accelerated fractionation to standard fractionation radiotherapy for head and neck squamous cell carcinomas: first report of RTOG 9003.

Authors:  K K Fu; T F Pajak; A Trotti; C U Jones; S A Spencer; T L Phillips; A S Garden; J A Ridge; J S Cooper; K K Ang
Journal:  Int J Radiat Oncol Biol Phys       Date:  2000-08-01       Impact factor: 7.038

8.  Meta-analysis of chemotherapy in head and neck cancer (MACH-NC): an update on 93 randomised trials and 17,346 patients.

Authors:  Jean-Pierre Pignon; Aurélie le Maître; Emilie Maillard; Jean Bourhis
Journal:  Radiother Oncol       Date:  2009-05-14       Impact factor: 6.280

Review 9.  Expanding role of the medical oncologist in the management of head and neck cancer.

Authors:  Nicholas Choong; Everett Vokes
Journal:  CA Cancer J Clin       Date:  2007-12-20       Impact factor: 508.702

10.  Hyperfractionated irradiation with or without concurrent chemotherapy for locally advanced head and neck cancer.

Authors:  D M Brizel; M E Albers; S R Fisher; R L Scher; W J Richtsmeier; V Hars; S L George; A T Huang; L R Prosnitz
Journal:  N Engl J Med       Date:  1998-06-18       Impact factor: 91.245
View more
  7 in total

1.  Management of locoregional recurrence in cutaneous squamous cell carcinoma of the head and neck.

Authors:  Ulrich Strassen; Benedikt Hofauer; Christian Jacobi; Andreas Knopf
Journal:  Eur Arch Otorhinolaryngol       Date:  2016-08-06       Impact factor: 2.503

2.  The Potential Impact of Connexin 43 Expression on Bcl-2 Protein Level and Taxane Sensitivity in Head and Neck Cancers-In Vitro Studies.

Authors:  Bianka Gurbi; Diána Brauswetter; Attila Varga; Pál Gyulavári; Kinga Pénzes; József Murányi; Veronika Zámbó; Ede Birtalan; Tibor Krenács; David Laurence Becker; Miklós Csala; István Vályi-Nagy; István Peták; Kornél Dános
Journal:  Cancers (Basel)       Date:  2019-11-22       Impact factor: 6.639

3.  IGF1R and Src inhibition induce synergistic cytotoxicity in HNSCC through inhibition of FAK.

Authors:  Christine E Lehman; Adam Spencer; Sarah Hall; Jeremy J P Shaw; Julia Wulfkuhle; Emanuel F Petricoin; Stefan Bekiranov; Mark J Jameson; Daniel Gioeli
Journal:  Sci Rep       Date:  2021-05-24       Impact factor: 4.996

4.  Prognostic value of aberrant promoter hypermethylation of tumor-related genes in early-stage head and neck cancer.

Authors:  Kiyoshi Misawa; Daiki Mochizuki; Atsushi Imai; Shiori Endo; Masato Mima; Yuki Misawa; Takeharu Kanazawa; Thomas E Carey; Hiroyuki Mineta
Journal:  Oncotarget       Date:  2016-05-03

5.  FRA1 promotes squamous cell carcinoma growth and metastasis through distinct AKT and c-Jun dependent mechanisms.

Authors:  Xiaoling Zhang; Joseph Wu; Suju Luo; Terry Lechler; Jennifer Y Zhang
Journal:  Oncotarget       Date:  2016-06-07

6.  eIF4E and 4EBP1 are prognostic markers of head and neck squamous cell carcinoma recurrence after definitive surgery and adjuvant radiotherapy.

Authors:  Chung-I Huang; Chih-Chun Wang; Tzong-Shyuan Tai; Tzer-Zen Hwang; Chuan-Chien Yang; Chin-Mu Hsu; Yu-Chieh Su
Journal:  PLoS One       Date:  2019-11-22       Impact factor: 3.240

7.  Piwi-Interacting RNA1037 Enhances Chemoresistance and Motility in Human Oral Squamous Cell Carcinoma Cells.

Authors:  Guanghui Li; Xi Wang; Chunmei Li; Shuang Hu; Zhixing Niu; Qiang Sun; Minglei Sun
Journal:  Onco Targets Ther       Date:  2019-12-04       Impact factor: 4.147
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.